Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
20. Dezember 2024 08:00 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:...
Altamira Therapeutics Provides Update on Nasdaq Listing
04. Oktober 2024 16:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the...
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
20. September 2024 09:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
19. September 2024 16:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
17. September 2024 17:00 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
06. Juli 2021 09:00 ET
|
Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
21. Juni 2021 08:30 ET
|
Auris Medical AG
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...